Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Video Library —November 1, 2021
Categories:Interview with the Innovators
Cleveland Clinic Taussig Cancer Center
Baylor Charles A. Sammons Cancer Center
Beth Israel Deaconess Medical Center, Harvard Medical School Teaching Hospital, Boston, MA
Last modified: November 15, 2022